Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D.
An Exciting Addition to the Palisade Bio Team
Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer.
A Leader in the Field
Dr. Jones brings with him a wealth of experience and expertise in the field of gastroenterology. With a background in both clinical practice and biotechnology entrepreneurship, he is uniquely positioned to drive forward Palisade Bio’s mission of developing innovative treatments for GI disorders.
Throughout his career, Dr. Jones has demonstrated a commitment to improving patient outcomes and advancing the field of gastroenterology. His passion for innovation and dedication to excellence make him an ideal fit for Palisade Bio.
An Inducement Grant for Excellence
As a testament to his exceptional qualifications, Dr. Jones has been awarded an inducement grant as part of his appointment. This grant recognizes his outstanding contributions to the field and underscores Palisade Bio’s commitment to attracting top talent.
With Dr. Jones at the helm as Chief Medical Officer, Palisade Bio is poised to make significant strides in the development of new therapies for GI complications. His leadership will be instrumental in shaping the future of the company and bringing much-needed relief to patients suffering from these conditions.
How This Appointment Will Affect Me
As a patient with gastrointestinal issues, Dr. Jones’s appointment gives me hope for improved treatment options in the future. His expertise and dedication to advancing the field of gastroenterology suggest that Palisade Bio will continue to make significant progress in developing innovative therapies for GI complications.
How This Appointment Will Affect the World
Dr. Jones’s appointment as Chief Medical Officer of Palisade Bio has the potential to impact the world by revolutionizing the treatment of GI disorders. His leadership and expertise will drive forward the development of new therapies that could benefit patients worldwide, ultimately improving outcomes and quality of life for individuals with gastrointestinal issues.
Conclusion
The appointment of Dr. Mitchell Jones as Chief Medical Officer of Palisade Bio marks an exciting chapter in the company’s journey towards advancing therapies for GI complications. With his leadership and expertise, Palisade Bio is well-positioned to make significant strides in the field of gastroenterology and bring much-needed relief to patients around the world.
